Drug Contracting: Bridging the Gap Between Value and Cost
READ MORE
Press Releases
In an industry often characterized by incremental changes, Girisha Fernando, the CEO and founder of Lyfegen, is making leaps. We sat down with Fernando to discuss the recent landmark partnership between Lyfegen and Newfoundland and Labrador Health Services—a collaboration that heralds a significant shift in the Canadian healthcare landscape.
Your partnership with Newfoundland and Labrador Health Services is quite a milestone. Can you share with us what this means for the current state of rebate management in Newfoundland?
Girisha Fernando (GF): Absolutely. This partnership is a transformative step for rebate management in Newfoundland. The current system, largely manual and complex, is ripe for innovation. With our digital platform, we're bringing a level of automation and accuracy that was previously unattainable. This means more efficient processing, less room for error, and a better allocation of resources, which is critical in healthcare.
That’s quite an advancement. And how does this impact the management of drug products, especially in areas like oncology?
GF: It’s a game-changer, especially for critical areas like oncology. Newfoundland and Labrador, as the first in Canada to use our platform, sets a precedent. The region, through the pan-Canadian Pharmaceutical Alliance, has been managing complex product listing agreements for drugs, including those for oncology. These agreements are vital for making treatments affordable. Our platform simplifies this, managing the various terms of these agreements efficiently, which is crucial for timely and affordable access to treatments.
It seems like a significant step forward for healthcare management. How does this align with the broader goals of Lyfegen?
GF: This partnership aligns perfectly with our goal to make healthcare more accessible and efficient. Automating the rebate process in Newfoundland and Labrador, especially for critical treatments in oncology, directly contributes to the sustainability and accessibility of healthcare treatments.
Looking to the future, what does this partnership mean for Lyfegen and healthcare systems globally?
GF: This is just the beginning. We're looking to extend our platform to healthcare systems around the world. Our aim is to make this technology a standard in healthcare management, fostering more efficient, sustainable, and equitable healthcare systems globally.
Read more about the partnership in the official press release.
.svg)
.svg)
.svg)
READ MORE
In an era of innovative therapies and escalating healthcare costs, drug contracting has become a cornerstone of sustainable healthcare delivery. Balancing the promise of cutting-edge treatments with financial realities poses a significant challenge for payers and pharmaceutical companies alike. In this blog, we’ll delve into how drug contracting is evolving to bridge the gap between value and cost and how Lyfegen’s solutions empower stakeholders to achieve this balance efficiently.
The healthcare industry faces a dual mandate: ensure patient access to life-saving treatments and maintain financial sustainability. This balance is particularly critical in the face of rising costs for innovative therapies such as gene and cell treatments, which can range from hundreds of thousands to millions of dollars per patient. For example, the average cost of some gene therapies exceeds $1 million per treatment, creating substantial financial pressure on healthcare systems and insurers.
At the heart of this challenge is the need for value-based frameworks that link reimbursement to patient outcomes. Traditional models—which rely on fixed pricing or volume-based discounts—are no longer adequate to address the uncertainties associated with high-cost therapies. These uncertainties include the long-term effectiveness of treatments, variability in patient response, and potential complications that may arise over time.
Moreover, there is increasing pressure from governments and regulatory bodies to ensure affordability without compromising access. For instance, in Europe, innovative reimbursement models are gaining traction, with over 50% of countries exploring outcome-based agreements as a way to manage budgetary constraints. Similarly, in Asia, the growing adoption of health technology assessments (HTAs) underscores the focus on aligning drug pricing with real-world effectiveness.
For payers, these dynamics mean embracing tools that provide clarity on financial risks while ensuring that patients receive timely access to treatments. Pharmaceutical companies, on the other hand, face the challenge of justifying the high costs of their therapies through transparent data and measurable outcomes. Success in this evolving landscape requires collaboration between stakeholders, data-driven decision-making, and the adoption of technology platforms that streamline the contracting process.
Traditional pricing models often struggle to account for the long-term impacts of high-cost therapies. To address these challenges, stakeholders are increasingly adopting value-based contracting models that tie payment to outcomes. However, implementing these models requires sophisticated data analysis, scenario planning, and a commitment to shared goals.
Lyfegen’s suite of tools is designed to simplify and optimize the drug contracting process, enabling payers and pharmaceutical companies to achieve their objectives efficiently. Here’s how:
1. Lyfegen Agreements Library: This comprehensive digital repository offers access to over 6,000 public agreements and 20 unique pricing models.
2. Lyfegen Drug Contracting Simulator: This tool empowers users to simulate pricing scenarios and evaluate their financial implications in real-time.
3. Lyfegen Rebate Analytics Platform (ARA): Optimize rebate management with seamless automation and centralized processes.
Adopting innovative drug contracting strategies can make the difference between missed opportunities and successful outcomes. Lyfegen’s solutions, are here to help you design contracts that balance value and cost effectively. Book your demo today to see how these tools can support your goals.
READ MORE
The first quarter of the year is a pivotal time for the pharmaceutical industry. As budgets are finalized and contracts renegotiated, Q1 sets the stage for how effectively organizations manage rebates, optimize costs, and deliver value.
For those navigating the complexities of pharma rebate management, Q1 offers unique opportunities to streamline workflows, review existing agreements, and ensure every rebate maximizes its potential. This period isn’t just about planning, it’s about implementing smarter processes to stay ahead in an increasingly dynamic healthcare landscape.
Why Rebate Management Deserves Q1 Attention
Q1 is the ideal time to evaluate rebate performance from the previous year. Were the agreements aligned with expectations? Did they deliver the promised value?
By assessing past performance, teams can identify underperforming agreements and opportunities for improvement. This ensures resources are allocated to agreements that drive measurable results.
Rebate workflows are often complex, requiring significant manual effort for tracking, reconciliation, and reporting. In Q1, organizations have the opportunity to implement systems that:
Streamlining workflows early in the year creates efficiencies that save time and resources throughout the year.
The first quarter is also critical for renegotiating rebate terms with manufacturers and payers. Updated contracts may include:
Teams equipped with data from previous agreements are better positioned to negotiate terms that align with strategic goals.
The Role of Technology in Pharma Rebate Management
Technology is transforming how organizations approach pharma rebate management. Tools like those offered by Lyfegen enable teams to:
For example, Lyfegen’s platform simplifies rebate tracking and provides actionable insights, ensuring organizations maximize their rebate potential while minimizing inefficiencies.
Start your year smarter!
Q1 is the time to rethink and refine your approach to pharma rebate management. With smarter workflows, clearer insights, and a focus on data-driven strategies, your team can unlock measurable savings and operational excellence.
Book a demo today to discover how Lyfegen’s solutions can simplify your rebate workflows and set you up for success in 2025.
Sign up & be the first to know about INNOVATIONS
* By sending this message, you agree to our privacy policy.
